Start › Szpiczak mnogi › Karolina Północna › Charlotte
Badania kliniczne dla Szpiczak mnogi w mieście Charlotte, NC
21 badań dla Szpiczak mnogi szuka uczestników w ośrodkach w mieście Charlotte i okolicach (w promieniu ok. 30 mil). Otwórz badanie, aby zobaczyć kryteria kwalifikacji i dane kontaktowe zespołu badawczego.
Oficjalny tekst badania (angielski)
Rekrutujesz uczestników do badania? Wyróżnij je na górze tej strony – $99 za 30 dni →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
RekrutacjaFaza 3
- Research Site, Charlotte
- Research Site, Charlotte
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
RekrutacjaFaza 1
- Levine Cancer Institute, Charlotte
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
RekrutacjaFaza 4
- Levine Cancer Institute, Charlotte
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
RekrutacjaFaza 2
- Atrium Health, Charlotte
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
RekrutacjaFaza 3
- Levine Cancer Institute, Charlotte
- Novant Health, Charlotte
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
RekrutacjaFaza 1/2
- Atrium Health Levine Cancer Institute, Charlotte
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RekrutacjaFaza 2
- Atrium Health's Levine Cancer Institute, Charlotte
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
RekrutacjaFaza 3
- Levine Cancer Institute, Charlotte
- Levine Cancer Institute, Charlotte
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RekrutacjaFaza 1/2
- Atrium Health Levine Cancer Institute /ID# 271510, Charlotte
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
RekrutacjaFaza 3
- Novant Health Cancer Institute, Charlotte
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
RekrutacjaFaza 1
- Atrium Health, Levine Cancer Institute, Charlotte
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
RekrutacjaFaza 1/2
- Research Site, Charlotte
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
RekrutacjaFaza 3
- Research Site, Charlotte
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
RekrutacjaFaza 1/2
- Atrium Health Levine Cancer Institute /ID# 276193, Charlotte
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
RekrutacjaBadanie obserwacyjneZapraszamy zdrowych ochotników
- Atrium Health Levine Cancer, Charlotte
Pre-malignant States to Hematologic Malignancies in Firefighters
RekrutacjaBadanie obserwacyjneZapraszamy zdrowych ochotników
- Levine Cancer Institute, Charlotte
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RekrutacjaFaza 3
- Levine Cancer Institute, Charlotte
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RekrutacjaFaza 2
- Levine Cancer Institute, Charlotte
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
RekrutacjaFaza 1/2
- Levine Cancer Institute, Charlotte
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
RekrutacjaFaza 3
- GSK Investigational Site, Charlotte
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
RekrutacjaFaza 1
- Levine Cancer Institute, Charlotte
Badania dla Szpiczak mnogi w innych miastach
- New York City, NY60 badań
- Boston, MA42 badań
- Atlanta, GA42 badań
- Houston, TX38 badań
- Durham, NC37 badań
- Nashville, TN32 badań
- Denver, CO27 badań
- Rochester, MN24 badań
- St. Louis, MO24 badań
- Columbus, OH24 badań
- Baldwin Park, CA23 badań
- Edison, NJ22 badań
Inne badania w mieście Charlotte
- Nowotwory (wszystkie typy)27 badań
- Rak piersi22 badań
- Niedrobnokomórkowy rak płuca19 badań
- Ostra białaczka szpikowa16 badań
- Otyłość16 badań
- Nadwaga15 badań
- Rak jelita grubego i odbytnicy13 badań
- Rak jajnika12 badań
- Niewydolność serca11 badań
- Nowotwór przerzutowy11 badań
- Rak płaskonabłonkowy głowy i szyi10 badań
- POChP9 badań
Źródło: ClinicalTrials.gov, dane pobrane 6 paź 2026. Każde badanie ustala własne kryteria kwalifikacji; zespół badawczy decyduje, kto może wziąć udział.